| 36.34 0.01 (0.03%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.82 | 1-year : | 50.01 |
| Resists | First : | 36.66 | Second : | 42.82 |
| Pivot price | 30.38  |
|||
| Supports | First : | 28.62 | Second : | 23.64 |
| MAs | MA(5) : | 36.34 |
MA(20) : | 28.99 |
| MA(100) : | 25.61 |
MA(250) : | 24.15 |
|
| MACD | MACD : | 3 |
Signal : | 2 |
| %K %D | K(14,3) : | 97.9  |
D(3) : | 98.5 |
| RSI | RSI(14): 84 |
|||
| 52-week | High : | 36.66 | Low : | 18.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PCRX ] has closed below upper band by 23.3%. Bollinger Bands are 455.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.43 - 36.61 | 36.61 - 36.76 |
| Low: | 35.88 - 36.09 | 36.09 - 36.27 |
| Close: | 36.03 - 36.35 | 36.35 - 36.63 |
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Sat, 17 Oct 2026
Pacira BioSciences stock at USD 36.34 on October 16, 2026, 0.90 percent below high - ad-hoc-news.de
Thu, 15 Oct 2026
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada
Thu, 15 Oct 2026
Doma Perpetual Capital Management LLC Sells Out Pacira BioScienc - GuruFocus
Wed, 14 Oct 2026
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
Wed, 14 Oct 2026
Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 13 Oct 2026
Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 40 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 112.9 (%) |
| Shares Short | 8,080 (K) |
| Shares Short P.Month | 7,330 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 1.9 % |
| Operating Margin | 6.1 % |
| Return on Assets (ttm) | 1.4 % |
| Return on Equity (ttm) | 2 % |
| Qtrly Rev. Growth | 6.1 % |
| Gross Profit (p.s.) | 14.8 |
| Sales Per Share | 18.69 |
| EBITDA (p.s.) | 3.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 188 (M) |
| Levered Free Cash Flow | 98 (M) |
| PE Ratio | 103.82 |
| PEG Ratio | 0.9 |
| Price to Book value | 2.15 |
| Price to Sales | 1.94 |
| Price to Cash Flow | 7.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|